Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments
Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime
May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide.
Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness through educational newsletters, social media campaigns and collaborations with dermatologists and other healthcare professionals. The Company also offers valuable resources and insights on its website to empower individuals to recognize the early warning signs of skin cancer and understand the benefits of non-invasive treatment.
"With the number of skin cancer cases on the rise, awareness and access to patient-friendly, non-invasive treatment options are more critical than ever," said Joe Sardano, CEO of Sensus Healthcare. "Our IG-SRT and SRT technologies exemplify our commitment to providing healthcare professionals with the tools they need to effectively treat skin cancer while prioritizing patient comfort and preserving healthy tissue."
IG-SRT and SRT-100 Vision, Sensus' flagship products that provide effective, non-invasive treatment options for non-melanoma skin cancers, are at the forefront of the Company's solutions to help patients achieve optimal outcomes with minimal side effects and no downtime. IG-SRT delivers precise, targeted radiation while the SRT-100 Vision integrates high-frequency ultrasound imaging for a precise treatment and an improved patient experience.
In conjunction with its focus on skin cancer awareness and education, and to expand access to its technologies, Sensus Healthcare offers a range of acquisition options such as its Fair Deal Agreement. This shared-revenue program has enjoyed considerable success since being launched just one year ago. The Fair Deal Agreement requires no upfront capital expenditure by a dermatology practice and is structured to remove any financial barrier to procuring state-of-the-art treatment solutions while enhancing patient outcomes and satisfaction.
Sensus invites investors, providers and other stakeholders to join its awareness efforts by participating in initiatives and helping to spread awareness about skin cancer. Together, we can make meaningful strides in promoting early detection and improving outcomes for those affected by skin cancer.
For more information about Sensus Healthcare, the Company's IG-SRT and SRT products, or its initiatives for Skin Cancer Awareness Month, please visit www.sensushealthcare.com.
Tips to Avoid Skin Cancer
While family history can play a role in the development of melanoma skin cancer, it is often caused by overexposure to ultraviolet (UV) rays from the sun or tanning beds. Although melanoma is the most aggressive form of skin cancer, it is also one of the most preventable. By taking simple precautions, you can significantly reduce your risk.
- Limit Sun Exposure: The best way to prevent melanoma is to reduce exposure to UV radiation. Try to avoid the sun during peak hours, typically between 10 a.m. and 4 p.m., when UV rays are the strongest.
- Wear Sunscreen: Use a broad-spectrum sunscreen with at least SPF 30 and reapply every two hours, or more frequently if swimming or sweating. Sunscreen helps protect your skin from harmful UV rays.
- Seek Shade: When spending time outdoors, stay in the shade as much as possible. This provides a natural barrier from the sun's rays.
- Wear Protective Clothing: Hats, sunglasses, and long-sleeved shirts made of tightly woven fabric can reduce direct sun exposure. Special sun-protective clothing is also available.
- Avoid Tanning Beds: Tanning beds emit harmful UV radiation, increasing the risk of melanoma and other skin cancers. Choose self-tanning products for a safer alternative.
- Perform Regular Skin Checks: Regularly examine your skin for unusual moles, spots or growths. Pay attention to changes in existing moles, such as size, shape or color. And remember to see your dermatologist every year for a full-body skin cancer screening.
About Skin Cancer
According to the American Academy of Dermatology, an estimated one in five Americans will develop skin cancer in their lifetime. Approximately 9,500 people in the U.S. are diagnosed with skin cancer every day and more than 1 million Americans are living with melanoma. Skin cancer can affect anyone, regardless of skin color, and skin cancer in patients with darker skin tones is often diagnosed in later stages, when it's more difficult to treat. Melanoma rates have been rising rapidly over the past 30 years, doubling from 1992 to 2011. Melanoma – the most serious type of skin cancer – now affects 1 in 29 men and 1 in 40 women in their lifetime.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250501778275/en/
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614